dipyridamole has been researched along with Diabetes, Phosphate in 1 studies
Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Seikaly, MG | 1 |
| Quigley, R | 1 |
| Baum, M | 1 |
1 trial available for dipyridamole and Diabetes, Phosphate
| Article | Year |
|---|---|
Effect of dipyridamole on serum and urinary phosphate in X-linked hypophosphatemia.
Topics: Adolescent; Adult; Calcitriol; Child; Cyclic AMP; Dipyridamole; Glomerular Filtration Rate; Humans; | 2000 |